Assuming regulatory approval, what role do you foresee for varegacestat (RINGSIDE) in the management of progressive desmoid tumors, particularly in relation to existing systemic treatment options?

Once daily dosing is certainly more attractive from patient perspective. Apart from that I do not foresee much differences in impact on how we manage desmoid tumors. Since this was also a placebo controlled trial, there is no way to judge it against nirogacestat.